Day One

• Reflecting on the evolution of the TPD field, from early degrader design principles to today’s landscape of molecular glues and emerging proximity modalities
• Showcasing latest advances from the Ciulli Lab in mechanistic understanding and chemical biology of degraders, including unpublished data on previously undruggable targets and ternary complex formation
• Highlighting collaborative academic and industry consortia tackling grand challenges in paediatric cancers and neurodegenerative diseases
• Exploring the translational frontier, from spin-out innovation and pharma partnerships to future directions that will define the next generation of proximity-based therapeutics

New Data

• Delivering first-in-human clinical findings from the world’s inaugural autophagy-targeting degrader for neurodegenerative disease
• Demonstrating safety, pharmacokinetics, and exposure outcomes from single- and multiple-ascending dose studies to validate clinical feasibility
• Advancing formulation and translational development of ATB2005A in canine dementia models to strengthen cross-species proof-of-concept and accelerate therapeutic advancement

Clinical Update

This networking session is your opportunity to get face-to-face with many of the brightest minds working in TPD and induced proximity to establish meaningful connections to pursue for the rest of the conference

• Examining emerging mechanistic principles governing molecular glue-induced degradation and target selectivity
• Optimising experimental and assay-based strategies to elucidate degradation pathways and functional outcomes
• Exploring opportunities to expand molecular glue applications beyond traditional mechanisms

New Data

• Elucidating the mechanistic drivers of ternary complex formation to improve predictability in molecular glue discovery
• Designing assays that detect and stabilise protein–protein interactions under the right biophysical conditions to enhance screening accuracy
• Applying mechanistic insights to build models that guide hit identification and inform future induced proximity modalities beyond molecular glues

New Data

• Evaluating the strengths and limitations of phenotypic screening for discovering novel proximity therapeutics
• Comparing biology-first versus chemistry-first approaches to proximity drug discovery
• Leveraging biology-first strategies to unlock non-degrader modalities such as stabilisers, modulators and activators by anchoring discovery in disease-relevant phenotypes and mechanistic pathways
• Addressing the complexity of biological assay readouts in non-oncology indications and discussing how inflammation, neurodegeneration and other areas challenge traditional screening assays

• Applying phenotypic and functional genomics screens to uncover novel E3 ligases with translational relevance
• Establishing mechanistic and in vivo validation to demonstrate degrader efficacy and tissue selectivity
• Exploring the potential for broad target applicability and therapeutic versatility of emerging ligase systems

New Data

Noval Ligase

• Integrating structural biology, bioinformatics and chemoinformatics to rationally design Targeted Glues™ that achieve selective degradation across diverse targets
• Demonstrating mechanistic insights and preclinical progress of SMART T degraders employing distinct E3 ligases to validate platform versatility
• Applying structure-guided principles to accelerate translation of novel glue–ligase combinations from discovery to clinical readiness

Noval Ligase

• Discussing the requirements of a successful molecular glue design platform
• Blending the speed and scalability of machine learning with the accuracy of physicsbased methods for optimal protein-protein matching and ternary complex structure prediction
• Computational design and experimental validation of optimised molecular glue degraders and activators

Contribute to the conversation and showcase your groundbreaking research in TPD and induced proximity drug discovery and development. To present a poster, register your place and submit an abstract highlighting your latest discovery

• Demonstrating how the AIMS (AI + MS) platform integrates AI modelling and structural proteomics to map protein interactions and inform degrader design
• Showcasing lead optimisation strategies to enhance efficacy, selectivity, and rational design of molecular glues and degraders
• Presenting preclinical results from Protai’s CAR-T6 degrader program as a case study of data-driven optimisation from discovery to in vivo validation

• Applying computational and AI-driven discovery workflows to design plant-specific degraders and glues with novel E3 ligases
• Translating human-targeted induced proximity principles into plant biology to expand modality reach beyond traditional therapeutics
• Exploring how agricultural molecular glues can inform next-generation discovery in human health through shared mechanistic insights